Navigation Links
New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response
Date:11/7/2011

er in patients with good/moderate RAPID3 (79.7%, n=246) or EULAR (78.5%, n=284) responses compared to those with poor RAPID3 (70.1%, n=117) or EULAR (68.4%, n=79) responses in the certolizumab pegol plus MTX group, according to Week 12 responses (last observation carried forward (LOCF)). At Week 52, good/moderate RAPID3 or EULAR responses were higher for those treated with certolizumab pegol plus MTX versus the RAPID3 (63.6%, n=44) or EULAR (69.2%, n=52) responses for those treated with placebo plus MTX, according to Week 12 responses (LOCF).

The analysis showed greater inhibition of radiographic progression in patients treated with certolizumab pegol plus MTX versus those treated with placebo plus MTX, regardless of the level of response (good, moderate, or poor) at Week 12 and how the response was determined (RAPID3 or DAS28). The analysis suggested that for patients receiving MTX, assessing RAPID3 response at Week 12 may be beneficial in aiding clinicians in treatment decisions.

Furthermore, the analysis revealed that at Week 12, the majority of certolizumab pegol plus MTX patients had good/moderate RAPID3 or EULAR responses (66.8% and 77.6% respectively, versus 23.5% and 29.1% for placebo plus MTX). At baseline, mean and median mTSS were similar between Week 12 response groups, and at one year, patients with a poor RAPID3 or EULAR response at Week 12 had a greater increase in mTSS from baseline than those patients with a good/moderate response. Differences between categories were greatest in the MTX alone group.

RAPID 1 showed certolizumab pegol had a low incidence of injection site pain (n=<3 new cases /100 years) and discontinuations due to adverse events (AEs). The most commonly occurring AEs were headache, nasopharyngitis, and upper respiratory tract infections. Reported serious adverse reactions were infections (including tuberculosis) and malignancies (including lymphoma), consistent with findings from other trials in the
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T
2. Rapid Fire Marketing: Medical Cannabis Management Signs Agreement with Second Non-Profit
3. Baxano Rapidly Expands Sales Force to Support Robust Demand for the iO-Flex® System
4. GNS Healthcare, Inc. Expands Senior Management Team to Leverage the Rapidly Growing Opportunities for Big Data in Healthcare Management
5. Trinity Pharma Solutions Brings SaaS Benefits to Life Sciences Industry with Rapid Access to Actionable Sales Intelligence
6. Scientific Presentations at 2011 AAPM/COMP Meeting Highlight TrueBeam® and RapidArc® Radiotherapy Systems From Varian Medical Systems
7. Researchers Find RapidArc® Radiotherapy from Varian Medical Systems Can Quickly and Accurately Deliver Total Marrow Irradiation (TMI) Treatments for Patients with Blood Cancers
8. Al Kindy Hospital in Morocco Carries Out First RapidArc® Radiotherapy Treatments in North Africa
9. Generex in Agreement to License RapidMist™ Technology for $10 Million to Amarantus BioSciences for Use With Its Proprietary MANF Proteins
10. Objet to Demonstrate One-of-a-Kind, Multi-Material 3D Printing Applications at Rapid 2011
11. Cimzia® (certolizumab pegol) Data Showed Rapid Improvement in Signs and Symptoms Predicted Better Long-Term Outcomes in Rheumatoid Arthritis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Research and Markets ... the "Investigation Report on China,s Latanoprost Market, ... Developed by Pharmacia & Upjohn in 1995, latanoprost ... reduces intraocular pressure. As the first pressure- lowering ... name of Xalatan) entered China ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015  Perrigo Company ... that it has completed the acquisition of leading OTC ... at €200 million. The transaction is a clear demonstration ... the Company,s leading European distribution network spanning 36 countries.  ... Joseph C. Papa commented, "We are excited to ...
(Date:8/28/2015)... y LONDRES, 28 de agosto de 2015 ... anunció hoy su participación en el  Congreso de ... soluciones cardiológicas más recientes y novedosas, entre ellas ... conectan a las personas y la tecnología con ... a diagnosticar, guiar los tratamientos y permitir atención ...
Breaking Medicine Technology:China Latanoprost Market Investigation Report 2015-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... businesses nationwide. Addictions specialist, Dr. James Strawbridge, gives a new approach on solutions ... it should begin with the employer and employees getting together for meaningful group ...
(Date:8/28/2015)... ... ... Gregory K. Toumayan, D.C., Q.M.E., is now treating patients with back pain and associated ... pain, stiffness, muscle spasms, and numbness. , Dr. Toumayan received his Bachelor of ... earn his title of Doctor of Chiropractic from the Palmer College of Chiropractic and ...
(Date:8/28/2015)... ... ... Mendon, IL, home of the Adams County Fairgrounds, was treated once again to ... In its second year, the “Music With A Mission” benefit concert was held there ... “Music With A Mission” is to raise money to help fund music education programs ...
(Date:8/28/2015)... , ... August 28, 2015 , ... The newest therapy ... be available for general use any time soon, according to educational website Surviving Mesothelioma. ... therapy that received orphan drug designation for mesothelioma last week from the FDA, will ...
(Date:8/28/2015)... ... August 28, 2015 , ... External Counterpulsation, also known as ... is now selling External Counterpulsation (EECP or ECP) machines with a full clinic licence ... been in business since 2007 helping people prevent and reverse heart disease ...
Breaking Medicine News(10 mins):Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2Health News:Buy New External Counterpulsation (EECP or ECP) With Heart Fit Clinic 2
... associated with age, might affect women with diabetes or ... recent study .// ,The study shows elderly ... and are at an increased risk for developing cognitive ... women with pre-diabetes or diabetes was increased nearly two-fold. ...
... say that they have now found out that long-term use ... of cancer.// ,The trial results of the longest follow-up ... show cardiovascular death was reduced by 17 percent and coronary ... drug simvastatin, also known as Zocor, for 10 years compared ...
... 600 babies in the United States is born with an isolated ... cleft only // and no other birth defects. ,Researchers say ... if a couple will have a child born with a cleft ... According to researchers isolated clefts happen during early fetal development. ...
... a degenerative joint disease and one of the oldest ... the joint’s cartilage breaks down and the bones rub ... ,An international, multi-center study shows an effective treatment ... as Prexige. The drug was found to reduces gastric ...
... public places can improve the overall likelihood someone will ... AEDs -- devices capable of shocking the heart back ... 1,000 shopping malls, apartment complexes, and other public places ... volunteers in these communities were then trained in either ...
... recent study researchers say cancer patients who receive treatment have ... new study shows many doctors are not taking the necessary ... more than 100 oncologists to determine if the doctors were ... preventative measures used by the physicians. About 40 percent of ...
Cached Medicine News:
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: